Indeed, CD19 CAR-T cells collected from patients with chronic lymphocytic leukemia who responded to therapy were not only polyfunctional, but persisted and maintained their polyfunctionality up to 4 years postinfusion (45). Here, CD19 is linked to B-cell chronic lymphocytic leukemia.